Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: Lack of changes after a neonatal bilateral lesion of the ventral hippocampus

Neurochemistry International

Volumn 34, Issue 3, 1999, Pages 235-244

  Lillrank, S M ^a   Lipska, B K ^a   Weinberger, D R ^a   Fredholm, B B ^b   Fuxe, K ^b   Ferre S ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 8 IODO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; RACLOPRIDE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; NEUROMODULATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SCHIZOPHRENIA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; FEMALE; HIPPOCAMPUS; MALE; PREGNANCY; PYRIMIDINES; RACLOPRIDE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; SALICYLAMIDES; SCHIZOPHRENIA; TRIAZOLES; XANTHINES;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS;

EID: 0032931759     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(99)00008-X     Document Type: Article

References (57)

1. 2 receptors: an autoradiographic analysis in rat brain. Brain Research Bulletin. 16:1986;517-525.
2. 1 receptors in brain demonstrated with digital substraction autoradiography. The Journal of Neuroscience. 7:1987;213-222.
3. 2A receptors in the nucleus accumbens mediate locomotor depression. Brain Research Bulletin. 31:1993;397-404.
4. Borison R.L., Hitri A., Blowers A.J., Diamond B. Antipsychotic drug action: clinical, biochemical and pharmacological evidence for site specificity of action. Clinical Neuropharmacology. 76:1983;137-150.
5. Brog J.S., Salyapongse A., Deutch A.Y., Zahm D.S. The patterns of afferent innervation of the core and shell in the 'accumbens' part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. The Journal of Comparative Neurology. 338:1993;255-278.
6. 2 receptors. Psychopharmacology. 74:1981;122-124.
7. 1 dopamine receptor in the rat brain: Quantitative autoradiographic localization using an iodinated ligand. Neuroscience. 26:1988;83-100.
8. 3H]raclopride binding to brain tissue from subjects with schizophrenia: Methodological aspects. Neuropharmacology. 36:1997;779-786.
9. 1-receptors in rat brain, as revealed by autoradiography. Neuroscience. 34:1990;759-769.
10. 2 receptors induces catalepsy. Neuroscience Letters. 130:1991;162-164.
11. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
12. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
13. 1 receptor antagonist binding sites. Neuroscience Letters. 208:1996;109-112.
14. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology. 133:1997;107-120.
15. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences. 20:1997;482-487.
16. 1 receptors in stably cotransfected fibroblast cells. The Journal of Biological Chemistry. 273:1998;4718-4724.
17. Fibiger H.C. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. Journal of Clinical Psychiatry. 55:(suppl B):1994;33-36.
18. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. The Journal of Neuroscience. 16:1996;2020-2026.
19. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacological Reviews. 46:1994;143-156.
20. Fuxe K., Ögren S.O., Fredholm B.B., Agnati L., Hökfelt T., Pérez de la Mora M. Possibilities of a differential blockade of central monoamine receptors. Ajuriaguerra J., Tissot R. Rhinencéphale Neurotransmitteurs et Psychoses, Symposium Bel-Air V. 1977;253-289 Georg & Cie, Genève.
21. Gerfen C.R., Wilson C.J. The basal ganglia. Swanson L.W., Björklund A., Hökfelt T. Handbook of Chemical Neuroanatomy. Vol. 12, Part III:1996;371-468 Elsevier, Amsterdam.
22. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annual Review of Neuroscience. 16:1993;299-321.
23. 3 receptors and use of antipsychotics in patients with schizophrenia. Archives of General Psychiatry. 54:1997;225-232.
24. 2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport. 8:1997;1515-1518.
25. 2A receptors in the nucleus accumbens and the caudate-putamen. European Journal of Pharmacology. 323:1997;127-131.
26. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Coughenour L.L., Downs D.A. Comparison of the behavioural effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology. 98:1989;31-37.
27. Heimer L., Zahm D.S., Alheid G.F. Basal ganglia. Paxinos G. The Rat Nervous System. 1995;579-628 Academic Press, San Diego.
28. Hess E.J., Bracha H.S., Kleinman J.E., Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sciences. 40:1987;1487-1497.
29. 2A receptors in rat brain: Comparison with dopamine receptors. Neuroscience. 80:1997;1187-1207.
30. 2 receptor interactins in animal models of schizophrenia. European Journal of Pharmacology. 295:1996;147-154.
31. 2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biological Psychiatry. 36:1994;827-835.
32. 3H]CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Research. 808:1998;320-323.
33. Lillrank S., Lipska B.K., Weinberger D.R. Neurodevelopmental animal models of schizophrenia. Clinical Neuroscience. 3:1995;98-104.
34. Lipska B.K., Weinberger D.R. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviour in the rat. Developmental Brain Research. 75:1993;213-222.
35. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology. 9:1993;67-75.
36. Lipska B.K., Weinberger D.R. Subchronic treatment with haloperidol or clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology. 10:1994;199-205.
37. Lipska B.K., Weinberger D.R. Gonadectomy does not prevent novelty- or drug-induced hyperresponsiveness in rats with neonatal excitotoxic hippocampal damage. Developmental Brain Research. 78:1994;253-258.
38. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes postpubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology. 122:1995;35-43.
39. 3 receptors, neurotensin and enkephalin mRNA in rats with neonatal lesions of the ventral hippocampus. Society for Neuroscience Abstracts. 23:1997;1361.
40. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol reagent. The Journal of Biological Chemistry. 193:1951;289-309.
41. 2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis. The Journal of Neuroscience. 10:1990;2587-2600.
42. Martin G.E., Rossi D.J., Jarvis M. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacology Biochemistry and Behaviour. 45:1993;951-958.
43. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
44. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. The Journal of Neuroscience. 15:1995;2186-2191.
45. Ögren S.O. The behavioural pharmacology of typical and atypical antipsychotic drugs. Csernansky J.G. Handbook of Experimental Pharmacology, Antipsychotics. Vol. 120:1996;225-265 Springer, Berlin.
46. 2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. Brain Research. 759:1997;41-49.
47. 2A Agonists: A potential new type of atypical antipsychotics. Neuropsychopharmacology. 17:1997;82-91.
48. 2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats, European Journal of Pharmacology (in press).
49. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
50. 3H]raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology. 109:1992;410-414.
51. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseased brain. Neuropsychopharmacology. 1:1987;5-15.
52. 4 receptors elevated in schizophrenia. Nature. 365:1993;441-445.
53. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Research. 681:1995;109-116.
54. Vahid-Ansari F., Robertson G.S. 7-OH-DPAT differentially reverses clozapine- and haloperidol-induced increases in Fos-like immunoreactivity in the rodent forebrain. European Journal of Neuroscience. 8:1996;2605-2611.
55. Weinberger D.R. From neuropathology to neurodevelopment. The Lancet. 346:1995;552-557.
56. 3 sites. Brain Research. 792:1998;324-326.
57. 2A adenosine receptor antagonist, to rat striatal membranes. British Journal of Pharmacology. 117:1996;1381-1386.